Telomere-targeting agent granted Rare Pediatric Disease designation
The US Food and Drug Administration (FDA) has designated MAIA Biotechnology’s immunotherapy THIO for the treatment of paediatric-type diffuse high-grade gliomas (PDHGG) as a drug for a rare paediatric disease.
“THIO is a versatile anti-cancer agent that has demonstrated positive results in multiple difficult to treat cancer types, including paediatric high-grade glioma, which is among the most treatment-resistant cancers in children. THIO is shown to activate the immune system while evading tumour immunosuppression, a novel therapeutic approach for this devastating childhood disease,” said MAIA Chairman and Chief Executive Officer Vlad Vitoc.
“We are proud to receive the FDA’s Rare Pediatric Disease designation for THIO, which significantly bolsters our plans for continuing research in the PDHGG indication.”
Previous research showcased THIO’s potency as a treatment for a PDHGG subtype known as diffuse intrinsic pontine glioma (DIPG).
A research collaboration between MAIA and Nationwide Children’s Hospital found that THIO combined with ionising radiation (IR) resulted in significantly decreased cell proliferation and produced potent anticancer effects in highly aggressive DIPG.
THIO is a first-in-class investigational telomere-targeting agent currently in clinical development for non-small cell lung cancer (NSCLC).
The modified nucleotide 6-thio-2’-deoxyguanosine (THIO) induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. THIO-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses.
The sequential treatment with THIO followed by PD-(L)1 inhibitors resulted in profound and persistent tumour regression in advanced, in vivo cancer models by induction of cancer type–specific immune memory.
In addition to its rare paediatric disease designation in PDHGG, THIO holds orphan drug designations (ODD) in three cancer types: hepatocellular carcinoma (HCC), small cell lung cancer (SCLC) and glioblastoma.
Diana Spencer, Senior Digital Content Editor, DDW
